Market Research Logo

Klebsiella Pneumoniae Infections - Pipeline Review, H2 2015

Klebsiella Pneumoniae Infections - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Klebsiella Pneumoniae Infections - Pipeline Review, H2 2015’, provides an overview of the Klebsiella Pneumoniae Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Klebsiella Pneumoniae Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Klebsiella Pneumoniae Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Klebsiella Pneumoniae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Klebsiella Pneumoniae Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Klebsiella Pneumoniae Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Klebsiella Pneumoniae Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Klebsiella Pneumoniae Infections Overview
Therapeutics Development
Pipeline Products for Klebsiella Pneumoniae Infections - Overview
Pipeline Products for Klebsiella Pneumoniae Infections - Comparative Analysis
Klebsiella Pneumoniae Infections - Therapeutics under Development by Companies
Klebsiella Pneumoniae Infections - Therapeutics under Investigation by Universities/Institutes
Klebsiella Pneumoniae Infections - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Klebsiella Pneumoniae Infections - Products under Development by Companies
Klebsiella Pneumoniae Infections - Products under Investigation by Universities/Institutes
Klebsiella Pneumoniae Infections - Companies Involved in Therapeutics Development
Arsanis Biosciences GmbH
Boehringer Ingelheim GmbH
Cellceutix Corporation
Debiopharm International S.A.
Evaxion Biotech
F. Hoffmann-La Roche Ltd.
FOB Synthesis, Inc.
Melinta Therapeutics, Inc
Merck & Co., Inc.
MicuRx Pharmaceuticals, Inc.
Nosopharm SAS
Novan, Inc.
Pfizer Inc.
Phico Therapeutics Limited
Procarta Biosystems Ltd
Sarepta Therapeutics, Inc.
Shionogi & Co., Ltd.
Soligenix, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Syntiron LLC
Tetraphase Pharmaceuticals Inc.
Theraclone Sciences, Inc.
Trana Discovery, Inc.
Klebsiella Pneumoniae Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASN-300 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CB-027 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CB-618 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CC-1807 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CTIX-1278 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Debio-1454 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dusquetide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FSI-1671 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FSI-1686 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GN snare - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IBN-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Klebsiella pneumoniae vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Klebsiella pneumoniae vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody for Klebsiella Pneumoniae Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MRX-V - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NOSO-95179 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVN-1000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Onc-72 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pneumonia vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PT-4 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PXS-4728A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RX-05 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RXP-792 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RXP-873 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-649266 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SM-295291 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SM-369926 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Gram-Negative Nosocomial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Klebsiella pneumoniae Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide for Gram-Negative Bacterial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide for Klebsiella Pneumoniae Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TP-076 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TP-138 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TP-600 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TP-6076 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Klebsiella Pneumoniae Infections - Recent Pipeline Updates
Klebsiella Pneumoniae Infections - Dormant Projects
Klebsiella Pneumoniae Infections - Discontinued Products
Klebsiella Pneumoniae Infections - Product Development Milestones
Featured News & Press Releases
Mar 09, 2015: Phico Therapeutics Receives Translation Award to Advance its SASPject PT4 Aimed at Escherichia coli and Klebsiella pneumoniae towards Clinical Trials
Sep 06, 2012: Cubist Pharma To Feature Antibiotic Drug Candidate CB-027 At ICAAC 2012
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Klebsiella Pneumoniae Infections, H2 2015
Number of Products under Development for Klebsiella Pneumoniae Infections - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2015
Klebsiella Pneumoniae Infections - Pipeline by Arsanis Biosciences GmbH, H2 2015
Klebsiella Pneumoniae Infections - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Klebsiella Pneumoniae Infections - Pipeline by Cellceutix Corporation, H2 2015
Klebsiella Pneumoniae Infections - Pipeline by Debiopharm International S.A., H2 2015
Klebsiella Pneumoniae Infections - Pipeline by Evaxion Biotech, H2 2015
Klebsiella Pneumoniae Infections - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Klebsiella Pneumoniae Infections - Pipeline by FOB Synthesis, Inc., H2 2015
Klebsiella Pneumoniae Infections - Pipeline by Melinta Therapeutics, Inc, H2 2015
Klebsiella Pneumoniae Infections - Pipeline by Merck & Co., Inc., H2 2015
Klebsiella Pneumoniae Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H2 2015
Klebsiella Pneumoniae Infections - Pipeline by Nosopharm SAS, H2 2015
Klebsiella Pneumoniae Infections - Pipeline by Novan, Inc., H2 2015
Klebsiella Pneumoniae Infections - Pipeline by Pfizer Inc., H2 2015
Klebsiella Pneumoniae Infections - Pipeline by Phico Therapeutics Limited, H2 2015
Klebsiella Pneumoniae Infections - Pipeline by Procarta Biosystems Ltd, H2 2015
Klebsiella Pneumoniae Infections - Pipeline by Sarepta Therapeutics, Inc., H2 2015
Klebsiella Pneumoniae Infections - Pipeline by Shionogi & Co., Ltd., H2 2015
Klebsiella Pneumoniae Infections - Pipeline by Soligenix, Inc., H2 2015
Klebsiella Pneumoniae Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
Klebsiella Pneumoniae Infections - Pipeline by Syntiron LLC, H2 2015
Klebsiella Pneumoniae Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2015
Klebsiella Pneumoniae Infections - Pipeline by Theraclone Sciences, Inc., H2 2015
Klebsiella Pneumoniae Infections - Pipeline by Trana Discovery, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Klebsiella Pneumoniae Infections Therapeutics - Recent Pipeline Updates, H2 2015
Klebsiella Pneumoniae Infections - Dormant Projects, H2 2015
Klebsiella Pneumoniae Infections - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Klebsiella Pneumoniae Infections, H2 2015
Number of Products under Development for Klebsiella Pneumoniae Infections - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report